Skip to main content
. Author manuscript; available in PMC: 2020 Oct 1.
Published in final edited form as: Hypertension. 2019 Sep 3;74(4):957–966. doi: 10.1161/HYPERTENSIONAHA.119.13430

Figure 4.

Figure 4.

Decreased OLA1 expression contributes to SOD2 deficiency in PPHN. (A) Dual immunofluorescence staining for αSMA (green), OLA1 and DAPI nuclear staining showing decreased OLA1 expression in distal-PAs from PPHN patients compared to infants without PPHN (n=4). (B) Immunoblottings showing decreased OLA1 expression in the lungs, PAs, isolated PAECs, and PASMCs from PPHN compared to control-lambs (n=7). (C) Western blots and bar charts showing decreased OLA1 expression and SOD2 activity OLA1-siRNA treated PAECs and controls, with or without acetylcholine treatments (n=5). (D) Bar charts showing increased O2¯-specific oxidized mitoSOX product, 2-OH-Mito-E+ formation in OLA1-silenced PAECs, scrambled-siRNA, and mito-TEMPO-treated OLA1 deficient PAECs (n=5). (E) Bar charts showing the effects of OLA1-siRNA, scrambled-siRNA, and Lenti-OLA1 on the SOD2 gene promoter activity in normal PAECs (n=4). *p<.05